A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

Trial Profile

A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 15 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.
    • 09 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top